US2018251543A1PendingUtilityA1

Polynucleotides encoding monoclonal antibodies that bind both il-17a and il-17f

Assignee: ZYMOGENETICS INCPriority: Mar 10, 2006Filed: May 15, 2018Published: Sep 6, 2018
Est. expiryMar 10, 2026(expired)· nominal 20-yr term from priority
A61P 37/02A61P 29/00A61P 11/06A61P 19/02A61K 2039/505C07K 2319/30G01N 33/6869C07K 2317/24G01N 2333/54C07K 2317/76C07K 2317/52C07K 2317/33Y10S530/809C07K 16/244C07K 2317/92C07K 16/468C07K 2317/31
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An isolated polynucleotide encoding a cross-reactive monoclonal antibody which specifically binds to both IL-17A (SEQ ID NO:2) and IL-17F (SEQ ID NO:4), wherein the monoclonal antibody inhibits the binding of both IL-17A and IL-17F to IL-17RC, and wherein the monoclonal antibody is a humanized monoclonal antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-7989. 
     
     
         2 . An expression vector comprising the following operably linked elements:
 a) a transcription promoter;   b) a DNA segment comprising the polynucleotide of  claim 1 ; and   c) a transcription terminator.   
     
     
         3 . An isolated host cell comprising the expression vector of  claim 2 . 
     
     
         4 . A method of producing a cross-reactive monoclonal antibody encoded by the DNA segment in the expression vector of  claim 2  comprising:
 culturing a host cell comprising said vector under conditions wherein the monoclonal antibody is expressed; and 
 recovering the monoclonal antibody.

Join the waitlist — get patent alerts

Track US2018251543A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.